Study for continuing or restarting cancer treatment that worked before
Treatments studied
Part of Cancer clinical trials.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign informed consent (agree to take part).
- You must already be eligible for treatment in the earlier “parent” study.
- You either paused treatment due to a long-lasting response, or you can restart it (“rechallenge”) based on the parent study rules.
- If you can get pregnant or you’re male and sexually active, you must follow the trial’s birth-control instructions.
- You should be receiving clinical benefit in the investigator’s judgment (not stopping because it isn’t helping).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This study lets people who already finished (or can no longer continue) an earlier AstraZeneca cancer treatment study keep receiving durvalumab. It tests whether continuing the same kind of treatment on a regular schedule can help keep your cancer under control.
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
This study lets people who are already benefiting from the cancer drug tucatinib keep taking it after their original study ends. It aims to provide continued access to the treatment while monitoring safety and effectiveness.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.